Experimental drug reduces “second stroke” after aneurysm rupture

01/02/2012 14:40:00

Font size:

Study Highlights: -An experimental drug reduced the risk of a blood vessel spasm after a ruptured brain aneurysm — a complication that can cause further brain damage. -However, researchers didn’t find a significant difference in the percentage of patients with poor functional outcome between those who got the drug and those who didn’t. -A larger trial is needed to determine whether the drug can improve overall outcomes, and how it would best fit with other treatments.

NEW ORLEANS — An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association’s International Stroke Conference 2012.

In patients with a subarachnoid hemorrhage, even after the burst weak spot in the vessel is closed, irritation from the initial bleeding can cause blood vessels to constrict, cutting off normal blood supply and resulting in even more brain damage. This is often called a “second stroke.” The vessel constriction is called angiographic vasospasm (VSP), which can occur about three to 14 days after aneurysm rupture.

“We don’t have very effective treatments for this complication,” said R. Loch Macdonald, M.D., study lead author and head of neurosurgery at St. Michael’s Hospital, University of Toronto in Ontario, Canada. “The treatment in use now is very expensive and risky and doesn’t work very well, and about half of the patients suffer permanent problems from it.”

The Effect of Clazosentan on Clinical Outcome after Aneurysmal Subarachnoid Hemorrhage and Endovascular Coiling (CONSCIOUS-3) Study included 571 patients with a ruptured aneurysm treated with an endovascular coil, a device used to repair the ruptured blood vessel.

Researchers divided patients into three groups, each given either a placebo, 5 mg clazosentan or 15 mg clazosentan. They halted CONSCIOUS-3 prematurely after patients in CONSCIOUS-2 (a trial of patients whose ruptured aneurysm was secured by coiling), which ran simultaneously, showed no benefit from the drug.

In CONSCIOUS-3, 27 percent of patients on placebo died, had vasospasm-related blood clots or neurological problems, or had rescue therapy to treat vasospasm, compared with 24 percent in the 5 mg/h and 15 percent in the 15 mg/h clazosentan groups. The odds of this combined endpoint were 53 percent lower at the higher clazosentan dose than with a placebo.

“Despite having less than half of the intended patients in the study, we were encouraged to see that at a high dose there was a significant reduction in vasospasm in patients initially treated with endovascular coiling,” Macdonald said.

In other findings:

Neurological deficits decreased with increasing clazosentan dose.
Rescue therapy was three times less in patients with 15 mg/h clazosentan (7 percent) compared to those receiving placebo (21 percent).
The occurrence of poor functional outcome or deaths within 12 weeks was not significantly different between placebo and medication groups.
Patients receiving clazosentan had more lung complications, anemia and low blood pressure than those on placebo.

“The data suggests that the drug is effective at reducing delayed cerebral ischemia, its side effect profile is acceptable, and further studies with different doses, administration regimens, and the avoidance of other vasodilators may allow an improvement in outcome to be demonstrated,” Macdonald said.

Co-authors are: Randall Higashida, M.D.; Emanuela Keller, M.D.; Stephan A. Mayer, M.D.; Andrew J. Molyneux, M.D.; Andreas Raabe, M.D.; Peter Vajkoczy, M.D.; Isabel Wanke, M.D.; Doris Bach, M.Sc.; Aline Frey, Pharm.D.; Pegah Nowbakht, Ph.D.; Sébastien Roux, M.D.; and Neal F. Kassell, M.D. Author disclosures are on the abstract.

Actelion Pharmaceuticals funded the study.

###

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding. External link

NR12-1002 (ISC 2012/ Macdonald)

Note: Actual presentation is 9:15 a.m. CT/ 10:15 a.m. ET, Wednesday, Feb. 1, 2012 in rooms 220-222.

Additional resources:

All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://newsroom.heart.org/pr/aha/_prv-experimental-drug-reduces-second-221514.aspx. Video clips with researchers/authors of studies will be added to this link after embargo. General ISC video and ISC photos will be updated during the meeting at newsroom.heart.org/ISC12-Video or newsroom.heart.org/ISC12-Photos.
Follow news from ASA International Stroke Conference 2012 via Twitter: http://twitter.com/#!/heartnews . Follow #ASANews12.

CONTACT:

ASA News Media Office in Dallas: (214) 706-1396

ASA News Media Office in New Orleans (Feb. 1-3): (504) 670-6010

For Public Inquiries: (800) AHA-USA1 (242-8721)

Add to: Add to your del.icio.us